Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 11/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708025 | 0.86 | CCR4 (0.76) | CCR4KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL28291947 | 0.85 | CCR4 (0.73) | CCR4KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21708018 | 0.84 | CCR4 (1.00) | CCR4KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21708002 | 0.83 | CCR4 (0.71) | CCR4KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL28297353 | 0.81 | CCR4 (0.68) | CCR4KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4561810 | 0.81 | CCR4 (0.68) | CCR4KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29274287 | 0.80 | CCR4 (0.67) | CCR4KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21708019 | 0.79 | CCR4 (1.00) | CCR4KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10078887 | 0.79 | MEN1 (1.00) | CCR4KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12603585 | 0.79 | CCR4 (0.64) | CCR4KMT2ARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062719-A1 | Application of Imidazopyridine Derivatives in Regenerative Medicine | UNIVERSITY OF HEIDELBERG (DE) | 2020-02-27 | — | — | US | disclosed |
| US-20200062719-A1 | Application of Imidazopyridine Derivatives in Regenerative Medicine | UNIVERSITY OF HEIDELBERG (DE) | 2020-02-27 | — | — | US | disclosed |
| EP-3611256-A1 | APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE | Universität Heidelberg (DE) | 2020-02-19 | — | — | EP | disclosed |
| EP-3611256-A1 | APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE | Universität Heidelberg (DE) | 2020-02-19 | — | — | EP | disclosed |
| US-20160318856-A1 | Substituted Urea eIF2alpha Kinase Activators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-20110117337-A1 | Magenta Dyes and Inks for Use in Ink-Jet Printing | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2011-05-19 | — | — | US | disclosed |
| US-20110117337-A1 | Magenta Dyes and Inks for Use in Ink-Jet Printing | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2011-05-19 | — | — | US | disclosed |
| WO-2010004312-A1 | MAGENTA DYES AND INKS FOR USE IN INK-JET PRINTING | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| US-7262204-B2 | Modulation of CCR4 function | AMGEN INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7144903-B2 | CCR4 antagonists | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1578341-A2 | MODULATION OF CCR4 FUNCTION | Tularik Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1578341-A4 | MODULATION OF CCR4 FUNCTION | TULARIK INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040039035-A1 | Modulation of CCR4 function | TULARIK INC. | 2004-02-26 | — | — | US | disclosed |
| US-20030018022-A1 | Ccr4 antagonists | TULARIK INC. | 2003-01-23 | — | — | US | disclosed |
| WO-2002094264-A1 | CCR4 ANTAGONISTS | TULARIK INC. (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020173524-A1 | Modulation of CCR4 function | TULARIK INC. (US) | 2002-11-21 | — | — | US | disclosed |
| WO-2002030358-A2 | MODULATION OF CCR4 FUNCTION | TULARIK INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018022-A1 | Ccr4 antagonists | CCR4, CCR1, CCR3 | CCR4 1/4885KMT2A 4260/4885RAB9A 3982/4885 |
| US-20020173524-A1 | Modulation of CCR4 function | CCR4, CCR1, CCR3 | CCR4 1/4885KMT2A 4488/4885RAB9A 3386/4885 |
| US-20160318856-A1 | Substituted Urea eIF2alpha Kinase Activators | EIF2AK1, EIF2A, EIF4A2 | CCR4 4642/4885KMT2A 635/4885RAB9A 1341/4885 |
| US-20040039035-A1 | Modulation of CCR4 function | CCR4, CCR1, CCR3 | CCR4 1/4885KMT2A 4488/4885RAB9A 3386/4885 |
| US-20200062719-A1 | Application of Imidazopyridine Derivatives in Regenerative Medicine | DOT1L, NSD1, KDM3A | CCR4 3403/4885KMT2A 55/4885RAB9A 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.